Engineered heart tissue: A novel tool to study the ischemic changes of the heart in vitro

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Katare, Rajesh G ^a,b   Ando, Motonori ^a   Kakinuma, Yoshihiko ^a   Sato, Takayuki ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CONNEXIN 43; CYCLOSPORIN A; PROTEIN BCL 2; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HEART CONTRACTION; HEART MUSCLE CELL; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONDUCTION SYSTEM; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HYPOXIA; IN VITRO STUDY; MECHANICAL STRESS; NONHUMAN; PROTEIN DEPHOSPHORYLATION; RAT; TISSUE ENGINEERING; ANIMAL; CELL CULTURE; CELL HYPOXIA; CULTURE TECHNIQUE; CYTOLOGY; ELECTRON MICROSCOPY; FEMALE; HEART; HEART MUSCLE; HUMAN; IMMUNOBLOTTING; METABOLISM; METHODOLOGY; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; ULTRASTRUCTURE; WISTAR RAT;

RATTUS;

ANIMALS; ANIMALS, NEWBORN; CELL CULTURE TECHNIQUES; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; CONNEXIN 43; FEMALE; HEART; HUMANS; IMMUNOBLOTTING; MICROSCOPY, ELECTRON; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR; TISSUE ENGINEERING;

EID: 77949514655     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009275     Document Type: Article

References (22)

1. Zimmermann WH, Fink C, Kralisch D, Remmers U, Weil J, et al. (2000) Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes. Biotechnol Bioeng 68: 106-114.
2. Zimmermann WH, Melnychenko I, Wasmeier G, Didie M, Naito H, et al. (2006) Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 12: 452-458.
3. Naito H, Melnychenko I, Didie M, Schneiderbanger K, Schubert P, et al. (2006) Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation 114: I72-78.
4. Zimmermann WH, Schneiderbanger K, Schubert P, Didie M, Munzel F, et al. (2002) Tissue engineering of a differentiated cardiac muscle construct. Circ Res 90: 223-230.
5. Sill B, Alpatov IV, Pacak CA, Cowan DB (2009) Implantation of engineered tissue in the rat heart. J Vis Exp.
6. Migneco F, Hollister SJ, Birla RK (2008) Tissue-engineered heart valve prostheses: 'state of the heart'. Regen Med 3: 399-419.
7. Stevens KR, Kreutziger KL, Dupras SK, Korte FS, Regnier M, et al. (2009) Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci U S A 106: 16568-16573.
8. Lesman A, Habib M, Caspi O, Gepstein A, Arbel G, et al. (2009) Transplantation of a Tissue-Engineered Human Vascularized Cardiac Muscle. Tissue Eng Part A.
9. Kaully T, Kaufman-Francis K, Lesman A, Levenberg S (2009) Vascularization-the conduit to viable engineered tissues. Tissue Eng Part B Rev 15: 159-169.
10. Katare RG, Ando M, Kakinuma Y, Arikawa M, Handa T, et al. (2009) Vagal nerve stimulation prevents reperfusion injury through inhibition of opening of mitochondrial permeability transition pore independent of the bradycardiac effect. J Thorac Cardiovasc Surg 137: 223-231.
11. Rajesh KG, Sasaguri S, Ryoko S, Maeda H (2003) Mitochondrial permeability transition-pore inhibition enhances functional recovery after long-time hypothermic heart preservation. Transplantation 76: 1314-1320.
12. Ando M, Katare RG, Kakinuma Y, Zhang D, Yamasaki F, et al. (2005) Efferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by preserving connexin43 protein. Circulation 112: 164-170.
13. Kakinuma Y, Ando M, Kuwabara M, Katare RG, Okudela K, et al. (2005) Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1alpha. FEBS Lett 579: 2111-2118.
14. Lin JW, Garber L, Qi YR, Chang MG, Cysyk J, et al. (2008) Region [corrected] of slowed conduction acts as core for spiral wave reentry in cardiac cell monolayers. Am J Physiol Heart Circ Physiol 294: H58-65.
15. Rajesh KG, Sasaguri S, Zhitian Z, Suzuki R, Asakai R, et al. (2003) Second window of ischemic preconditioning regulates mitochondrial permeability transition pore by enhancing Bcl-2 expression. Cardiovasc Res 59: 297-307.
16. Katare RG, Zhitian Z, Sodeoka M, Sasaguri S (2007) Novel bisindolylmaleimide derivative inhibits mitochondrial permeability transition pore and protects the heart from reperfusion injury. Can J Physiol Pharmacol 85: 979-985.
17. Akins RE (2002) Can tissue engineering mend broken hearts? Circ Res 90: 120-122.
18. Bailey B, Izarra A, Alvarez R, Fischer KM, Cottage CT, et al. (2009) Cardiac stem cell genetic engineering using the alphaMHC promoter. Regen Med 4: 823-833.
19. Shimizu T, Sekine H, Yamato M, Okano T (2009) Cell sheet-based myocardial tissue engineering: new hope for damaged heart rescue. Curr Pharm Des 15: 2807-2814.
20. Song H, Yoon C, Kattman SJ, Dengler J, Masse S, et al. (2009) Regenerative Medicine Special Feature: Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue. Proc Natl Acad Sci U S A.
21. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, et al. (1979) Myocardial infarct size and ventricular function in rats. Circ Res 44: 503-512.
22. Hasenfuss G (1998) Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 39: 60-76.